Literature DB >> 17497103

[What does HPV vaccination mean for gynecologic cancer screening?].

K U Petry1.   

Abstract

Human papilloma viruses (HPV) of the high-risk type cause almost all cervical carcinomas and some other anogenital tumors. Development of a carcinoma is uncommon; most infections heal spontaneously. When carcinomas develop, the latent phase is at least 8, more often 15-30 years. A negative HPV test thus excludes the risk of developing cervical carcinoma for many years. The approved vaccine against HPV 6/11/16/18 and the soon-to-be-approved one against HPV 16/18 are extremely safe and effective. Vaccinated individuals are almost 100% protected by the vaccines containing virus-like particles. Current studies suggest that 70-80% of high-grade cervical neoplasias can be avoided, as well as other vaginal, vulvar, and anal neoplasias. The yearly costs for treating precursors of these cancers exceed the cost of vaccinating all girls born in a given year. Thus HPV vaccination is cost effective, even when a modified cancer screening program is retained.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497103     DOI: 10.1007/s00105-007-1340-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  17 in total

1.  Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barbara Romanowski; Cecilia M Roteli-Martins; David Jenkins; Anne Schuind; Sue Ann Costa Clemens; Gary Dubin
Journal:  Lancet       Date:  2006-04-15       Impact factor: 79.321

2.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

3.  Decreasing rates of cervical cancer among American Indians and Hispanics in New Mexico (United States).

Authors:  A Chao; T M Becker; S W Jordan; R Darling; F D Gilliland; C R Key
Journal:  Cancer Causes Control       Date:  1996-03       Impact factor: 2.506

4.  Factors associated with an increased risk of prevalent and incident grade III cervical intraepithelial neoplasia and invasive cervical cancer among women with Papanicolaou tests classified as grades I or II cervical intraepithelial neoplasia.

Authors:  K Ulrich Petry; Gerd Böhmer; Thomas Iftner; Philip Davies; Oliver Brummer; Henning Kühnle
Journal:  Am J Obstet Gynecol       Date:  2002-01       Impact factor: 8.661

5.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

6.  A controlled trial of a human papillomavirus type 16 vaccine.

Authors:  Laura A Koutsky; Kevin A Ault; Cosette M Wheeler; Darron R Brown; Eliav Barr; Frances B Alvarez; Lisa M Chiacchierini; Kathrin U Jansen
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

7.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.

Authors:  G Y Ho; R D Burk; S Klein; A S Kadish; C J Chang; P Palan; J Basu; R Tachezy; R Lewis; S Romney
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

8.  A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions.

Authors:  M Dürst; L Gissmann; H Ikenberg; H zur Hausen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

9.  A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer.

Authors:  M Boshart; L Gissmann; H Ikenberg; A Kleinheinz; W Scheurlen; H zur Hausen
Journal:  EMBO J       Date:  1984-05       Impact factor: 11.598

10.  Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients.

Authors:  K-U Petry; S Menton; M Menton; F van Loenen-Frosch; H de Carvalho Gomes; B Holz; B Schopp; S Garbrecht-Buettner; P Davies; G Boehmer; E van den Akker; T Iftner
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

View more
  1 in total

Review 1.  [Differential diagnosis of condylomata acuminata. Indication for histopathology].

Authors:  G Gross
Journal:  Hautarzt       Date:  2009-06       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.